Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Feb 15, 2025; 17(2): 101780
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.101780
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.101780
Variables | TSAOs (n = 122) | TSADs (n = 71) | P value |
Age (years), mean ± SD (range) | 61.1 ± 14.5 (18.0-84.0) | 66.7 ± 11.8 (36.0-85.1) | 0.072 |
Sex | 0.234 | ||
Male | 63 (51.6) | 30 (42.3) | |
Female | 59 (48.4) | 41 (57.7) | |
BMI (n = 499), mean ± SD (range) | 24.1 ± 3.7 (17.4-37.7) | 23.7 ± 2.9 (17.7-30.6) | 0.128 |
Obesity | 0.726 | ||
Underweight (< 18.5) | 3 (2.5) | 3 (4.2) | |
Normal (18.5-23.0) | 46 (37.7) | 30 (42.3) | |
Overweight (23.0-25.0) | 31 (25.4) | 14 (19.7) | |
Obesity (≥ 25.0) | 42 (34.4) | 24 (33.8) | |
Alcohol | 0.177 | ||
None | 52 (42.6) | 37 (52.1) | |
Quit | 31 (25.4) | 20 (28.2) | |
Current | 39 (32.0) | 14 (19.7) | |
Smoking | 0.681 | ||
None | 82 (67.2) | 52 (73.2) | |
Quit | 23 (18.9) | 11 (15.5) | |
Current | 17 (13.9) | 8 (11.3) | |
Hypertension | 45 (36.9) | 36 (50.7) | 0.061 |
Diabetes mellitus | 29 (23.8) | 11 (15.5) | 0.171 |
Dyslipidemia | 21 (17.2) | 10 (14.1) | 0.568 |
Anti-platelet agent (n = 49) | 0.521 | ||
Aspirin | 23 (18.9) | 9 (12.7) | |
Warfarin/NOAC | 3 (2.5) | 2 (2.8) | |
Dual anti-platelet agent | 9 (7.4) | 3 (4.2) | |
History of colorectal cancer | 16 (13.1) | 11 (15.5) | 0.671 |
Symptom | 0.051 | ||
None | 111 (91.0) | 57 (80.3) | |
Gastrointestinal bleeding | 10 (8.2) | 14 (19.7) | |
Obstruction | 1 (0.8) | 0 (0.0) | |
Lesion-related factors | |||
Size (mm), mean ± SD (range) | 12.7 ± 8.0 (3.0-55.0) | 27.3 ± 15.9 (5.0-70.0) | 0.003 |
Diminutive (1-5 mm) | 16 (13.1) | 0 (0.0) | |
Small (6-9 mm) | 31 (25.4) | 15 (21.1) | |
Large (> 10 mm) | 75 (61.5) | 56 (78.9) | |
Location | 0.177 | ||
Cecum | 1 (0.8) | 2 (2.8) | |
Ascending colon | 13 (10.7) | 14 (19.7) | |
Transverse colon | 12 (9.8) | 8 (11.3) | |
Descending colon | 8 (6.6) | 1 (1.4) | |
Sigmoid colon | 42 (34.4) | 18 (25.4) | |
Rectum | 46 (37.7) | 28 (39.4) | |
Color | 0.001 | ||
White | 63 (51.6) | 19 (26.8) | |
Red | 59 (48.4) | 52 (73.2) | |
Morphology (Paris classification) | 0.005 | ||
0-Ip, 0-Isp | 53 (43.4) | 32 (45.1) | |
0-Is | 35 (28.7) | 32 (45.1) | |
0-IIa | 30 (24.6) | 4 (5.6) | |
0-IIa + IIc | 4 (3.3) | 3 (4.2) | |
Border | < 0.001 | ||
Distinct | 114 (93.4) | 50 (70.4) | |
Irregular | 8 (6.6) | 21 (29.6) | |
Mucosal surface | 0.058 | ||
Smooth | 62 (50.8) | 27 (38.0) | |
Lobular | 60 (49.2) | 44 (62.0) | |
Associated lesion (n = 104, 53.9%) | |||
Non-neoplastic lesions (n = 17, 8.8%) | 5 (4.2) | 12 (16.2) | < 0.001 |
Hyperplastic polyp | 5 (4.2) | 12 (16.2) | |
Neoplastic lesions (n = 87, 45.1%) | 48 (40.3) | 39 (52.7) | < 0.001 |
Sessile serrated lesion | 1 (0.8) | 1 (1.4) | |
Traditional serrated adenoma | 3 (2.5) | 7 (9.5) | |
Conventional adenoma with LGD | 37 (31.1) | 25 (33.8) | |
Conventional adenoma with HGD/ADC | 7 (5.9) | 6 (8.1) | |
Procedure-related factors | |||
Removal methods | < 0.001 | ||
Cold biopsy | 1 (0.8) | 0 (0.0) | |
Cold EMR | 6 (4.9) | 0 (0.0) | |
Conventional EMR | 97 (79.5) | 24 (44.4) | |
ESD | 13 (10.7) | 22 (40.7) | |
Operation | 3 (2.5) | 8 (14.8) | |
Observation | 2 (1.6) | 0 (0.0) | |
Post-procedural complications (n = 93, 48.2%) | < 0.001 | ||
Bleeding | 44 (36.1) | 48 (67.6) | |
Perforation | 1 (0.8) | 0 (0.0) | |
Treatment method of complication | < 0.001 | ||
APC | 15 (12.3) | 3 (4.2) | |
Coagrasper | 17 (13.9) | 18 (25.4) | |
Hemoclipping | 13 (10.7) | 27 (38.0) |
- Citation: Kim KH, Myung E, Oh HH, Im CM, Seo YE, Kim JS, Lim CJ, You GR, Cho SB, Lee WS, Noh MG, Lee KH, Joo YE. Clinical and endoscopic characteristics of colorectal traditional serrated adenomas with dysplasia/adenocarcinoma in a Korean population. World J Gastrointest Oncol 2025; 17(2): 101780
- URL: https://www.wjgnet.com/1948-5204/full/v17/i2/101780.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i2.101780